New CRISPR Technique Switches Genes On Without Cutting DNA, Offering Safer Path to Gene Therapy

Scientists have developed a new form of CRISPR-based gene editing that can switch genes on without ever cutting DNA — a fundamental departure from the molecular scissors approach that has defined gene therapy since CRISPR was first applied to human cells, and a potential breakthrough for the safe treatment of genetic diseases including sickle cell anemia, thalassemia, and certain cancers. The technique, described in Nature Communications by researchers at the University of New South Wales in Sydney and collaborators at St. Jude Children's Research Hospital in Memphis, uses a modified CRISPR system to deliver enzymes that strip methyl groups from specific points on DNA — lifting a molecular "lock" that silences certain genes without creating any breaks in the genome that could cause dangerous off-target mutations.

Methylation — the addition of a chemical methyl group to a DNA base — is one of the primary mechanisms by which cells regulate gene expression, switching genes off without deleting or altering the underlying genetic code. The UNSW-led team showed that by removing these methyl groups from silenced genes, they could reactivate those genes in human cells. Crucially, when they added methyl groups back, the genes switched off again, demonstrating precise bidirectional control. The finding settles a long-running debate in epigenetics about whether methylation is merely correlated with gene silencing or actively causes it. "This directly proves that methylation controls gene expression," said senior author Dr. Ozren Bogdanovic. "The debate is over."

The medical significance of this capability is substantial. In sickle cell anemia, the defective adult hemoglobin gene causes red blood cells to distort into crescent shapes that block capillaries and cause severe pain crises. Patients carry a fetal hemoglobin gene that could compensate for the defective adult version — but that gene is silenced by methylation shortly after birth and remains switched off throughout life. Previous efforts to reactivate fetal hemoglobin have involved cutting DNA, which carries risks of off-target mutations that could cause cancer or other complications. The UNSW approach removes the methyl groups that silence the fetal hemoglobin gene without cutting anything, potentially offering a far safer therapeutic pathway. Early laboratory experiments in cell lines showed the technique could substantially increase fetal hemoglobin production.

The new method is an example of "epigenetic editing" — modifying the chemical marks on DNA rather than the DNA sequence itself. Unlike conventional CRISPR gene cutting, where changes are permanent and potentially heritable, epigenetic edits are reversible, which could allow physicians to fine-tune gene activity like a dimmer switch rather than toggling it permanently on or off. This reversibility also means that if an epigenetic therapy causes unexpected side effects, doctors could in principle reverse the edit. Researchers caution that epigenetic modifications can be erased by cellular division and may not persist indefinitely in all tissues, raising questions about the durability of therapeutic effects that will need to be addressed in animal and clinical studies.

The broader implications of the finding extend well beyond sickle cell disease. The same methylation mechanisms that silence the fetal hemoglobin gene operate across thousands of other genes throughout the genome, many of which are inappropriately silenced in cancer cells, in aging tissues, or in rare genetic disorders caused by gene silencing rather than gene deletion. Pharmaceutical companies including Pfizer, Novartis, and several gene-editing startups have been monitoring epigenetic editing research for potential therapeutic applications. The CRISPR field's transition from cutting to rewriting to now simply unsilencing — without cutting at all — represents a maturation of the technology's therapeutic toolkit that could make gene-based medicine both safer and more broadly applicable than it has been to date.